Hantavirus Has Low Pandemic Risk But Moderna Stays Vigilant
Three deaths on board a cruise ship have caused concern, but the Andes hantavirus strain remains a low pandemic risk and vaccine firm Moderna will not accelerate development of its preclinical candidate.
Scrip - May 20, 2026

GHO and CBC Merger Creates World’s Largest Healthcare Investor
The pact will combine the financial firms’ complementary strengths across Asia-Pacific, North America and Europe, creating an investment manager with more than $21bn in assets.
Scrip - May 20, 2026

Labio 4.0: Integration From The Outset
How Morpho, Alfasigma’s CDMO business unit, is rethinking pharmaceutical development through integrated analytics, formulation, and GMP manufacturing.
Scrip - May 20, 2026

Takeda Reels From $885m Amitiza Reverse-Payment Verdict
Takeda faces more than $2.5bn in potential exposure after a landmark Amitiza pay-for-delay verdict that found its Par settlement delayed generic competition through a non-cash reverse payment and implicit no-AG pact.
Scrip - May 20, 2026

Eisai Expects Leqembi Expansion Through Iqlik And BBM Diagnosis
Growth for mainstays and Alzheimer's drug Leqembi helped Eisai's revenue double, with new formulations, indications and diagnostic tools seen boosting the amyloid-targeting antibody this fiscal year.
Scrip - May 20, 2026

Are One-Day Inspections Of ‘Low-Risk’ Facilities A Waste Of Time, Or A Good Use Of FDA Resources?
The US Food and Drug Administration launched a one-day inspections pilot in April. Under the program, the FDA will carry out one-day inspections of facilities that AI has designated as low risk. The FDA says these assessments will augment, not replace, standard inspection protocol.
Medtech Insight - May 19, 2026

Philips SmartIQ Improves Images, Slashes Radiation Dose – But Trial Data’s Still To Come
The system, built on the existing ClarityIQ platform, uses over 50% less X-ray radiation than the lowest-dose settings previously available on Azurion – with a blinded clinical study suggesting improved image quality in the majority of comparisons.
Medtech Insight - May 19, 2026

TEMPO Door Still Open, FDA Clarifies In FAQ Update
The US Food and Drug Administration is still accepting statements of interest from potential participants in its TEMPO pilot, which offers some enforcement discretion for makers of digital health products whose devices can benefit Medicare patients with certain chronic conditions.
Medtech Insight - May 19, 2026

Europe Cautiously Moves Toward PCCP Implementation
PCCPs are becoming an important part of AI device regulation, but so far are only “peppered” into EU legislation.
Medtech Insight - May 19, 2026

Shiseido Sees Green Shoots Of Recovery At US Business
Japanese cosmetics multinational Shiseido reports growing US sales in Q1 following a difficult 2025.
HBW Insight - May 20, 2026

Ibuprofen And Diclofenac Added To EU Priority Water Pollutants List
The EU has added ibuprofen and diclofenac to its list of priority water pollutants under revised water legislation, while leaving widely used OTC ingredients such as paracetamol, aspirin and naproxen off the list.
HBW Insight - May 20, 2026

Diamantas Extends Olive Branch To US FDA Staff Amid Senior Leader Shake-Up
Acting CDER Director Tracy Beth Høeg, who had been in the position about six months, was one of several senior leaders appointed by former commissioner Martin Makary to depart.
HBW Insight - May 20, 2026

Samsung Bioepis Expands Into Japan With Ustekinumab Launch
Samsung Bioepis has taken a step into the Japanese biosimilars market with the launch of its SB17 ustekinumab rival to Stelara through local partner Nipro. However, it will face stiff competition from multiple other players.
Generics Bulletin - May 20, 2026

Lupin Marks A Return To $1bn Annual US Sales
Lupin hit $1bn in US sales once before but then spent years clawing its way back. Now it's back, bigger, and betting biosimilars will keep the momentum going.
Generics Bulletin - May 20, 2026

For European Biosimilars, ‘Science Prevails Here’
Closing Medicines for Europe’s biosimilars conference, EMA chief medical officer Steffen Thirstrup said biosimilar regulation must continue evolving with science, as Europe enters a “Biosimilars 2.0” era shaped by comparability, convergence and uneven access challenges.
Generics Bulletin - May 20, 2026

Krka: Generics Winners Must Guarantee Uninterrupted Supply
Krka CEO Jože Colari? tells Generics Bulletin why vertical integration, manufacturing continuity and portfolio breadth are becoming decisive advantages in generics, as the Slovenian firm scales investment across Europe, India and China.
Generics Bulletin - May 20, 2026

The Biopharma A List: Taking The Pulse of Newco Creation In 2025
Biopharma Series A financing remained steady in 2025, reflecting stable new company creation year over year.
In Vivo - May 20, 2026

What’s Next For US FDA: Can Acting FDA Chief Diamantas Repair Makary’s Damage Before Drift Sets In?
With the former commissioner’s top lieutenants being replaced, Acting Commissioner Kyle Diamantas has moved fast to clean house and pacify career staff. But reversing 14 months of norm erosion is harder than changing the nameplate, if it’s even possible at all.
In Vivo - May 20, 2026